Veralox Therapeutics
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
diabetes
Technologies
AI Companies (Drug Discovery) Pharmaceutical and Drug DiscoveryR&D Platform
12-lipoxygenase (12-LOX) is an enzyme in the arachidonic acid (AA) pathway that oxidizes AA resulting in the production of 12-HETE. High 12-LOX activity and 12-HETE production have been linked to numerous syndromes and diseases, with elevated levels of serum 12-HETE having potential implications as a predictive biomarker for T1D.
Pipelines
No pipelines published yet
Products
Services
No services posted yet
